Cargando…

Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates

Non-human primates (NHPs) remain the most relevant challenge model for the evaluation of HIV vaccine candidates; however, discrepancies with clinical trial results have emphasized the need to further refine the NHP model. Furthermore, classical evaluation of vaccine candidates is based on endpoints...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrera, Carolina, Veazey, Ronald, Lemke, Melissa M., Arnold, Kelly, Kim, Jerome H., Shattock, Robin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879115/ https://www.ncbi.nlm.nih.gov/pubmed/35214645 http://dx.doi.org/10.3390/vaccines10020187

Ejemplares similares

ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone
por: Costanzo, Margaret C., et al.
Publicado: (2023)

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
por: Zolla-Pazner, Susan, et al.
Publicado: (2013)

P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand
por: Kaewkungwal, J, et al.
Publicado: (2009)

Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
por: Ratto-Kim, Silvia, et al.
Publicado: (2015)

Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2011)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial
por: Kim, JH, et al.
Publicado: (2009)

P19-51 LB. Improvement of the efficacy of ALVAC-HIV vaccine candidates for humans in non human primates
por: Franchini, G
Publicado: (2009)

The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans
por: Herrera, Carolina, et al.
Publicado: (2022)

Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
por: Vaccari, Monica, et al.
Publicado: (2019)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination
por: Tomalka, Jeffrey Alan, et al.
Publicado: (2021)

Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells
por: Harenberg, Anke, et al.
Publicado: (2008)

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
por: Easterhoff, David, et al.
Publicado: (2020)

Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial
por: Gombe, Ben, et al.
Publicado: (2022)

Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo
por: Crakes, Katti R, et al.
Publicado: (2020)

A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells
por: Eller, Michael A., et al.
Publicado: (2011)

The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy)
por: Angel, Jonathan B., et al.
Publicado: (2015)

Use of Nonhuman Primate Models to Develop Mucosal AIDS Vaccines
por: Genescà, Meritxell, et al.
Publicado: (2010)

ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2019)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
por: Moodie, Zoe, et al.
Publicado: (2020)

The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-γ by Natural Killer (NK) cells enhancing Th1 polarization
por: Ryan, Elizabeth J., et al.
Publicado: (2007)

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2020)

Evaluation of ex vivo produced endothelial progenitor cells for autologous transplantation in primates
por: Qin, Meng, et al.
Publicado: (2018)

RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues
por: Liyanage, NP, et al.
Publicado: (2012)

Efficient ex vivo expansion of conserved element vaccine-specific CD8+ T-cells from SHIV-infected, ART-suppressed nonhuman primates
por: Dross, Sandra, et al.
Publicado: (2023)

The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models
por: Herrera, Carolina
Publicado: (2019)

Efficient expression of self-complementary AAV in ganglion cells of the ex vivo primate retina
por: Koilkonda, Rajeshwari D., et al.
Publicado: (2009)

Ex vivo Culture and Contractile Force Measurements of Non-human Primate Heart Slices
por: Poch, Christine M., et al.
Publicado: (2023)

Ex vivo response to mucosal bacteria and muramyl dipeptide in inflammatory bowel disease
por: Loganes, Claudia, et al.
Publicado: (2016)

Microfluidic organotypic device to test intestinal mucosal barrier permeability ex vivo
por: Cherwin, Amanda E., et al.
Publicado: (2023)

Safety and efficacy of ex vivo expanded CD34(+) stem cells in murine and primate models
por: Zhang, Yu, et al.
Publicado: (2019)

Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models
por: Tuero, Iskra, et al.
Publicado: (2014)

Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice
por: Van Roey, Griet A, et al.
Publicado: (2012)

Convection Enhanced Delivery: A Comparison of infusion characteristics in ex vivo and in vivo non-human primate brain tissue
por: Miranpuri, Gurwattan, et al.
Publicado: (2013)

Informed consent disclosure to vaccine trial subjects of risk of COVID‐19 vaccines worsening clinical disease
por: Cardozo, Timothy, et al.
Publicado: (2020)

Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina
por: Hickey, D G, et al.
Publicado: (2017)

Engagement of monocytes, NK cells, and CD4(+) Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIV(mac251) vaginal acquisition
por: Gorini, Giacomo, et al.
Publicado: (2020)

Improving Defences at the Portal of HIV Entry: Mucosal and Innate Immunity: A summary report from a Global HIV Vaccine Enterprise Working Group
por: Shattock, Robin J, et al.
Publicado: (2008)

ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study
por: Saba, Corey, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vrlennl5ko80ubjmh026u0qq79